Advertisement
Screener

Vivos Therapeutics, Inc. (VVOS) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures

2.8 / 5 stars · 68/120 Roast Me

Vivos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures

Vivos Therapeutics, Inc. (VVOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures of 11.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures · last filed 2026-08-14

  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2025-12-31 was 16.00K shares.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2024-12-31 was 0.00 shares.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2024-09-30 was 0.00 shares.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2024-06-30 was 13.00K shares.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2025 was 751.00K shares, a 3029.17% increase from fiscal 2024.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2024 was 24.00K shares, a 52.00% decline from fiscal 2023.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2023 was 50.00K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 month
2026-06-3011.00K shares
10-Q · filed 2026-08-14
2025-12-3116.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
751.00K shares
10-K · filed 2026-04-15
2025-09-30735.00K shares
10-Q · filed 2025-11-19
2024-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
0.00 shares
derived: sum of 2 quarters · filed 2026-04-15
13.00K shares
derived: sum of 3 quarters · filed 2026-04-15
24.00K shares
10-K · filed 2026-04-15
2024-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
13.00K shares
derived: sum of 2 quarters · filed 2024-11-14
24.00K shares
10-Q · filed 2024-11-14
2024-06-3013.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
24.00K shares
10-Q · filed 2024-08-14
2024-03-3111.00K shares
10-Q · filed 2024-05-14
2023-12-3150.00K shares
10-K · filed 2025-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
NEXGEL, INC. (NXGL)United States$0.002B
INVO Fertility, Inc. (IVF)United States$0.002B-0.71
Catheter Precision, Inc. (VTAK)United States$0.002B-0.23
Tenon Medical, Inc. (TNON)United States$0.002B
Autonomix Medical, Inc. (AMIX)United States$0.004B
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Profusa, Inc. (PFSA)United States$0.002B
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Bluejay Diagnostics, Inc. (BJDX)United States$0.004B